Please ensure Javascript is enabled for purposes of website accessibility

Walgreen Passes Q4 Physical

By Timothy M. Otte – Updated Apr 5, 2017 at 8:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Slower growth doesn't slow down this drugstore giant.

Walgreen's (NYSE:WAG) cheeks may not quite have a rosy glow, but all vital signs pointed toward solid health in its fourth-quarter checkup earlier this week.

The company's 8.8% sales growth may have paced behind top-line growth trends of the recent past, but it remains impressive in light of today's economic environment. Many other top-notch retailers, like Best Buy (NYSE:BBY), are falling short of historical growth rates, while weaker players like Circuit City (NYSE:CC) seem to be on their last legs.

Though comps slipped from previous quarters, they still ran 2.6% higher year over year. In my opinion, positive comps are the first and most important vital sign for any retailer. In addition, the company reported market-share gains against its leading competitors in 58 of its top 60 product categories, according to ACNielsen rankings.

Gross margin slipped 40 basis points year over year. Management admitted on the call that it invested more heavily than usual in promotional activity, but the experiment didn't drive enough traffic to pay for itself. The company will "moderate" its promotional activity in the future. Though this overinvestment amounted to roughly $0.01 to $0.02 per share for the quarter, I don't fault the company for trying to squeeze a few more dollars from unusually tight-fisted consumers.

Expense growth of 5.5%, on nearly 9% higher sales, looks exceptional at first glance. But expenses were actually around 8% greater when you back out an adjustment for vacation accruals. I still think leveraging expenses in the face of gradually slowing sales growth is a solid accomplishment. Walgreen made tighter expense management a top priority nine months ago, and it's following through on that promise.

All this added up to earnings of $443 million, up 11.7 % year over year. Backing out the vacation accrual, the bottom line actually fell by 8%.

Is now a good time to buy Walgreen? Given the market's incredible recent volatility, I understand that Foolish investors may be more focused on what Congress and the Federal Reserve are doing (or not doing, for that matter). And Walgreen remains locked in a battle with CVS Caremark (NYSE:CVS) over who'll acquire Longs Drug (NYSE:LDG), leaving a minor halo of uncertainty over the stock.

Still, Walgreen trades at less than 15 times trailing-12-month earnings, a valuation we haven't seen in more than 10 years. That might be worth a nibble when the credit-market dust settles.

Further Foolishness:

Fool contributor Timothy M. Otte surveys the retail scene from Dallas. He welcomes comments on his articles, but doesn't own shares of any of the companies mentioned in this article. The Fool has a disclosure policy. Best Buy is a Stock Advisor and Inside Value selection and the Fool owns shares of it.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.69 (-0.43%) $0.14
Best Buy Co., Inc. Stock Quote
Best Buy Co., Inc.
BBY
$65.32 (-5.03%) $-3.46
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$97.74 (-0.62%) $0.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.